# US 5,346,813 A · Method of screening for small cell lung carcinoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,346,813 A
- Document ID: US5346813A
- Status: Granted
- Kind: A
- Application number: 07/982,112
- Filed: 1992-11-25
- Granted: 1994-09-13
- Earliest claimed: 1989-12-05
- Assignees: Boehringer Mannheim GmbH
- Inventors: Heinz Bodenmuller; Andreas Dessauer
- Web page: https://patentgrep.com/patent/US5346813A

## CPC

- G01N 33/5752: of the lungs
- Y10S 436/813: Cancer
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

In order to detect a small cell lung carcinoma, synaptophysin, its oligomers and/or its fragments are determined in body fluids.

## Claims

### Claim 1

A method of screening for small cell lung carcinoma comprising,
contacting a body fluid sample with antibodies or antibody fragments which specifically bind synaptophysin,
detecting at least one member of the group consisting of synaptophysin monomers, synaptophysin oligomers, and synaptophysin fragments,
wherein the presence of synaptophysin in the body fluid sample is associated with the presence of small cell lung carcinoma.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said body fluid sample is serum.

### Claim 3 (depends on 1)

The method according to claim 1, wherein said antibodies or antibody fragments specifically bind synaptophysin sequences which protrude from a vesicle membrane.

### Claim 4 (depends on 3)

The method according to claim 3, wherein said antibodies are directed against a carboxy-terminal end of said synaptophysin.

### Claim 5 (depends on 3)

The method according to claim 3 wherein antibodies directed against a translation product of a clone fragment pSR.sup.1 or fragments thereof are used to detect said synaptophysin.

### Claim 6 (depends on 3)

The method according to claim 3 wherein said antibodies are directed against an amino acid sequence 207 to 296 of a carboxy-terminal end of human synaptophysin.

### Claim 7 (depends on 3)

The method according to claim 3 wherein said antibodies are directed against an amino acid sequence 219-307 of a carboxy-terminal end of rat synaptophysin.

### Claim 8 (depends on 3)

The method according to claim 3, wherein said antibodies are directed against a 90 amino acid portion of a carboxy-terminal end of human synaptophysin.

### Claim 9 (depends on 8)

The method according to claim 8, wherein said 90 amino acid portion is the last 90 amino acids of said carboxy terminal end.

### Claim 10 (depends on 3)

The method according to claim 3, wherein said antibodies are monoclonal antibody SY38 derived from cell line ECACC 89112801.

### Claim 11 (depends on 3)

The method according to claim 3 wherein said antibodies are fragments of antibodies.

### Claim 12 (depends on 11)

The method according to claim 11, wherein said fragments of antibodies are Fab and/or F(ab').sub.2.

### Claim 13

A method of screening for small cell lung carcinoma comprising,
contacting a serum sample with antibodies or antibody fragments which specifically bind synaptophysin,
detecting at least one member of the group consisting of synaptophysin monomers, synaptophysin oligomers, and synaptophysin fragments,
wherein the presence of synaptophysin in the serum sample is associated with the presence of small cell lung carcinoma.

### Claim 14 (depends on 13)

The method according to claim 13, wherein said antibodies or antibody fragments specifically bind synaptophysin sequences which protrude from a vesicle membrane.

### Claim 15 (depends on 14)

The method according to claim 14, wherein said antibodies are directed against a carboxy-terminal end of said synaptophysin.

### Claim 16 (depends on 14)

The method according to claim 14 wherein antibodies directed against a translation product of a clone fragment pSR.sup.1 or fragments thereof are used to detect said synaptophysin.

### Claim 17 (depends on 14)

The method according to claim 14 wherein said antibodies are directed against an amino acid sequence 207 to 296 of a carboxy-terminal end of human synaptophysin.

### Claim 18 (depends on 14)

The method according to claim 14 wherein said antibodies are directed against an amino acid sequence 219-307 of a carboxy-terminal end of rat synaptophysin.

### Claim 19 (depends on 14)

The method according to claim 14, wherein said antibodies are directed against a 90 amino acid portion of a carboxy-terminal end of human synaptophysin.

### Claim 20 (depends on 14)

The method according to claim 14, wherein said 90 amino acid portion is the last 90 amino acids of said carboxy terminal end.

### Claim 21 (depends on 14)

The method according to claim 14, wherein said antibodies are monoclonal antibody SY38 derived from cell line ECACC 89112801.

### Claim 22 (depends on 14)

The method according to claim 14 wherein said antibodies are fragments of antibodies.

### Claim 23 (depends on 22)

The method according to claim 22, wherein said fragments of antibodies are Fab and/or F(ab').sub.2.